Concepedia

Author

Giovanni Donadoni

San Raffaele University of Rome

Also Known As

G Donadoni, G. Donadoni, Giovanni Donadoni

20

Publications

444

Citations

8

H-Index

11

Concepts

All Affiliations

San Raffaele University of RomeVita-Salute San Raffaele UniversityMolMed (Italy)
GD

About

Giovanni Donadoni is an author at San Raffaele University of Rome specializing in oncology, medicine, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

101

2

Immunology

1

1

49

3

Pathology

1

1

49

4

Pharmacology

1

1

52

5

Cancer Therapeutics

1

1

52

Giovanni Donadoni

×

7

Publications

413

Citations

7

H-Index

YearCitations

High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial

Andrés J.M. Ferreri, Giovanni Donadoni, Maria Giuseppina Cabras,

Journal of Clinical Oncology

2015

115

Risk‐tailored <scp>CNS</scp> prophylaxis in a mono‐institutional series of 200 patients with diffuse large B‐cell lymphoma treated in the rituximab era

Andrés J.M. Ferreri, Marta Bruno‐Ventre, Giovanni Donadoni,

British Journal of Haematology

2014

103

Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors

Vanesa Gregorc, Filippo de Braud, Tommaso Martino De Pas,

Clinical Cancer Research

2011

54

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours

Vanesa Gregorc, Giovanni Citterio, Giordano Vitali,

European Journal of Cancer

2009

52

High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial

Andrés J.M. Ferreri, Marianna Sassone, Barbara Kiesewetter,

Annals of Oncology

2015

49

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma

Armando Santoro, Tiziana Pressiani, Giovanni Citterio,

British Journal of Cancer

2010

30

A dose‐dense short‐term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high‐risk Burkitt lymphoma or high‐grade B‐cell lymphoma: safety and efficacy results of the “CARMEN” phase II trial

Andrés J.M. Ferreri, Chiara Cattaneo, Arben Lleshi,

British Journal of Haematology

2020

10

Page 1